Podcasts about regulatory

Regulatory systems are infamous for creating “traps” in seem to be impervious to reform. Regulators seek to “drain the swamp,” but, instead, find themselves up to their necks in alligators.Original article: https://mises.org/mises-wire/moloch-regulatory-state

Regulatory systems are infamous for creating “traps” in seem to be impervious to reform. Regulators seek to “drain the swamp,” but, instead, find themselves up to their necks in alligators.Original article: https://mises.org/mises-wire/moloch-regulatory-state

In this special Bowel Sounds and Nutrition Pearls collaboration episode, hosts Dr. Jennifer Lee and dietitian Nikki Misner speak with dietitian Lisa Richardson on infant formula. Lisa Richardson is a pediatric clinical dietitian and nutrition educator who brings together experience in pediatric specialty care, public health nutrition, and continuing education. She currently practices at UNC Children's Primary and Specialty Care Clinic. Across her publications, presentations, and clinical resources, Lisa focuses on making nutrition science usable, turning complex evidence into practical guidance that supports families, children, and the care teams who serve them.  Nutrition Pearls is supported by an educational grant from Mead Johnson Nutrition.Resources: Larson-Nath, et al. Term infant formula macronutrient composition: An update for clinicians. JPGN. 2025;80(5):751-759. doi:10.1002/jpn3.70002Rodrigo ML, et al.. Infant formula ingredients: Updates for clinicians.. 2024;78(5):1005-1008. doi:10.1002/jpn3.12192Lewis, et al. Reference Values for Macronutrients in Human Milk: the Mothers, Infants and Lactation Quality (MILQ) Study. Adv Nutr. 2025;16 Suppl 1(Suppl 1):100501. doi:10.1016/j.advnut.2025.100501Taylor SN, Buck CO. Post-discharge nutrition to optimize preterm infant short- and long-term outcomes. Semin Fetal Neonatal Med. 2025;30(2):101637. doi:10.1016/j.siny.2025.101637Abrams SA, et al. Food and Drug Administration Expert Panel on Infant Formula "Operation Stork Speed" June 2025: Part 1, Nutrient Considerations. Adv Nutr. 2026;17(4):100583. doi:10.1016/j.advnut.2025.100583Abrams SA, et al. Food and Drug Administration Expert Panel onInfant Formula "Operation Stork Speed" June 2025: Part 2, Regulatory and SafetyConsiderations. Adv Nutr. 2026;17(4):100584. doi:10.1016/j.advnut.2025.100584Abrams SA, et al. Food and Drug Administration Expert Panel on Infant Formula "Operation Stork Speed" June 2025: Part 3, Marketing of Infant Formulas, Breastfeeding Support, Hypoallergenic Formulas, and Nutrition for Preterm Infants. Adv Nutr. 2026;17(4):100585. doi:10.1016/j.advnut.2025.100585Pediatric Blue Book - Create personalized formula recipes and plans, and calculate nutritional needs using the dietitian-led, volunteer-run platform CDC Infant Formula Preparation and Storage Website U.S. FDA Infant Formula Homepage- Information on Operation Stork Speed, Closer to Zero Initiative, as well as view the listing of all non-exempt and exempt infant formulas that are currently available on the U.S. market.Produced by: Corey IrwinNASPGHAN - Council for Pediatric Nutrition Professionalscpnp@naspghan.org

Maureen Testoni, the stalwart president and CEO of the renowned 340B Health Program, will join the long-running Monitor Mondays todiscuss Eli Lilly's escalating demands for hospitals to submit in-house claims data as a condition of receiving 340B drug discounts. Who will blink first?Register now to reserve your participation.Broadcast segments will also include these instantly recognizable features:·      Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. ·      The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. ·      Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.·      Legislative Update: Folana Houston, legislative affairs analyst for Zelis, will report on current healthcare legislation.

I keep being accused of using AI. I've even been accused, more than once, of being AI-generated. So I owe you something better than irritation: an actual explanation of where I stand.In this episode, I work through the real concerns: the scraping of artists' work, the environmental cost, algorithmic bias, the fear of job displacement, the worry about deskilling, and argue that every one of them is a problem of how, not of whether. They are arguments for regulation, not for personal abstention. I talk about my own practice (yes, AI images sometimes; yes, Grammarly; no, not the writing or the thinking), about teaching at university in the middle of all this, and about why, as an anthropologist, I think this debate is really a debate about authorship and authenticity wearing a technological costume.The question, in the end, was never if AI. It was always, only, how.CONNECT & SUPPORT

Zum Newsletter anmelden und Updates direkt am Montag morgen per Mail erhalten: https://bit.ly/newslettersustaind | Einfach auf "Subscribe" klicken Imprint: www.sustaind.de

Jack Burnham examines the Pentagon's 1260H list, which identifies Chinese companies allegedly assisting the PRC's military-industrial base, signaling increased regulatory scrutiny for these entities. Burnham recommends streamlining government lists to prevent companies from exploiting gaps and advises retail investors of the national security risks these firms pose. (6)1919

TODAY ON THE ROBERT SCOTT BELL SHOW: LIVE from Reno Nevada, Jonathan Emord, Bill Gates Influence Scandal, Pesticide Cancer Ruling, Joel Salatin Farm Freedom, Democrats Prefer Leaving, Vaccine Study Blowback, OB/GYN CDC LOL, Brain Death Reflections, Grocery Additives, Sugary Beverage Liver Cancer, and MORE! https://robertscottbell.com/jonathan-emord-bill-gates-nih-influence-scandal-pesticides-cancer-ruling-joel-salatin-regulatory-freedom-55-percent-of-democrats-prefer-leaving-vaccine-study-blowback-vaccine-safety-concerns-ob/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Health Canada has issued an interim Letter of No Objection that opens the door for broader use of spray drones in Canadian agriculture, a move industry leaders say will help growers protect crops in fields that are inaccessible to conventional equipment. The letter follows Health Canada's February proposal to allow drones to apply any crop... Read More

Randy Fearnow speaks with Jaya White, Partner, Quarles & Brady LLP, about the regulatory landscape surrounding the growing home infusion industry. They discuss issues related to the Medicare HIT benefit; home infusion-specific state licensure requirements; ambulatory infusion suites, IV hydration clinics, and med spas; Indiana's recent requirement that their Medicaid home care providers must also be certified for Medicare; and the regulatory definition of “homebound.” Jaya co-wrote an article for Health Law Connections about this topic. From AHLA's Post-Acute and Long Term Services Practice Group.Watch this episode: https://www.youtube.com/watch?v=9rd5xivY2YkRead Jaya's Health Law Connections article: https://www.americanhealthlaw.org/content-library/connections-magazine/article/488ffc74-684d-4c97-882c-eae034db75fa/Navigating-Regulatory-Pitfalls-at-the-Nexus-BetweeLearn more about AHLA's Post-Acute and Long Term Services Practice Group: https://www.americanhealthlaw.org/practice-groups/practice-groups/post-acute-and-long-term-servicesEssential Legal Updates, Now in AudioAHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.Stay At the Forefront of Health Legal EducationLearn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/. 

Scott Ensign, Chief Strategy Officer at Butler/Till, joins Ari Paparo to discuss the advantages of being a 100% employee-owned agency, the rise of agentic AI in media buying, AdCP adoption, and the future of pharmaceutical advertising. Learn how Butler/Till is leveraging AI-powered workflows, healthcare expertise, mobile gaming inventory, and programmatic innovation to drive growth in a rapidly evolving media landscape. Takeaways Butler/Till operates as a 100% employee-owned ESOP, giving employees ownership stakes and allowing the agency to remain independent and agile. The agency is a women-owned and women-led business, with roughly two-thirds of employees being women. Thanks to its status as an independent agency, Butler/Till can operate with agility, making faster decisions and investing strategically without outside shareholder pressure. Butler/Till takes a product-focused approach, building technology and solutions around client needs rather than creating products solely for commercialization. Pharmaceutical advertising is shifting away from broad-reach TV campaigns toward addressable, data-driven digital media channels. Even if pharmaceutical advertising regulations change, opportunities will remain through disease-state education and targeted healthcare professional outreach. Mobile gaming remains an undervalued advertising channel, particularly for reaching healthcare professionals during everyday moments. Butler/Till participated in one of the industry's earliest agentic AI-powered media transactions using AdCP technology. Agentic AI can automate traditionally manual workflows such as RFPs, publisher negotiations, and media planning. The agency views AI primarily as a tool for accelerating work and solving talent shortages rather than replacing employees. Chapters00:00 Introduction to Scott Ensign and Butler/Till00:41 What makes Butler/Till unique as an employee-owned agency01:24 The history behind Butler/Till's ESOP structure02:25 Independent agencies vs. holding companies03:47 Product development and technology investments at Butler/Till04:33 Why Butler/Till hired a Chief Product Officer05:08 How clients approach AI and workflow innovation06:33 The changing landscape of pharmaceutical advertising08:31 Regulatory concerns and the future of pharma marketing10:44 Reaching healthcare professionals in the digital age12:15 Why mobile gaming is an overlooked advertising opportunity14:19 Butler/Till's early agentic AI and AdCP media transaction16:25 How buyer and seller AI agents could negotiate media deals19:28 Why pharma is a strong fit for agentic media buying21:24 Expanding AdCP into audio and offline media channels23:01 AI, efficiency, and the future of agency work23:57 Butler/Till's growth, hiring plans, and closing thoughts Guests: Ari Paparo, Scott Ensign Learn more about your ad choices. Visit megaphone.fm/adchoices

This was a fun discussion about the serious issue of gasoline, diesel, and fertilizer price increases for farmers, ranchers, and consumers in California. Make no mistake, the actions taken by the Newsom administration have driven consumer prices to some of the highest in the United States. Gavin has taken California from almost energy independent to total dependence on imports.We have Mike Ariza, a downstream expert, who has been on the podcast several times. A great resource for boots-on-the-ground information on the California downstream market. Connect with Mike on his X account. @MikeAriza4531Also, we had Joseph Huitt, who is with the Bordin-Huitt California Almond Ranch. Check out their family products for honey and specialty almonds at https://bhalmondranch.com/1. California's Energy Crisis & Fuel DependencyMike Ariza, an energy expert, explains that California has become dangerously dependent on fuel imports (40% dependent). Two major refineries were converted to renewable diesel in 2023, taking 350,000 barrels of crude oil processing offline. This resulted in no gasoline or jet fuel production from those facilities. The Iranian conflict further disrupted supply chains, cutting off jet fuel, diesel, and gasoline shipments from Asian refineries. President Trump's waiver of the Jones Act allowed fuel from Gulf Coast refineries to reach California, preventing potential $10+ gasoline prices and shortages.2. Agricultural Challenges & Rising CostsJoseph from Borden Hewitt Ranch discusses the severe economic pressures on family farms:Red Diesel prices skyrocketed from $3.17/gallon in February to $4.79-$6.60/gallon by MarchFertilizer costs doubled from $300-$500/acre to $400-$700/acre due to Strait of Hormones closureAlmond prices have remained below the $2/pound break-even point for five yearsPayment delays: Farmers receive paychecks every 3-4 months, not weekly, creating cash flow challenges3. Water Rights & Agricultural RestrictionsJoseph describes severe water restrictions in California's San Joaquin Valley, where farmers are prohibited from irrigating during peak heat seasons (June-July) despite canals being full. Banks only finance half the land value due to water limitations, effectively halving farm viability.4. Regulatory Overreach & Equipment RestrictionsEPA regulations prevent farmers from repairing their own equipment without manufacturer accessA diesel mechanic was jailed for helping farmers and truckers repair enginesSoftware restrictions: Farmers can't access tractor software updates, limiting their ability to fix equipment independentlyTuning restrictions: Rice farmers need extra horsepower to navigate clay fields but face penalties if caught modifying engines5. GMO Seeds & Agricultural ContractsDiscussion about restrictive seed contracts where farmers must purchase new seeds annually and cannot replant saved seeds from previous years, creating ongoing dependency on seed companies.6. State Taxes & Economic BurdenMultiple taxes burden California farmers:Cap and Invest (called "Theft and Invest")Road taxes37 cents for bullet train funding80 cents for other state initiatives These taxes are passed directly to consumers through higher food prices.7. Food Supply Chain VulnerabilityIf California loses refinery capacity, diesel shortages would collapse logistics, resulting in:Only 3-5 days of food supply in metropolitan areasPort of Los Angeles unable to operateFood distribution across the entire country disrupted (LA is the largest food importer during winter)8. Family Farm Viability & Future GenerationsJoseph, at 25 years old, represents the challenge facing young farmers. While passionate about farming, he's pursuing a master's degree in biological science (studying avian influenza) because farming alone cannot support a family. His mother advised all children to pursue other careers while farming as a side activity—a common reality for modern family farms.Overall Theme: The podcast highlights how interconnected energy, agriculture, and regulatory policy are in California, and how state policies are making it increasingly impossible for family farms to survive while threatening regional and national food security.Hat tip to the Great John Rich for being named the Special Envoy to Farmers for the USDA. We have reached out to him to see about getting him on the podcast.Check out the Energy News Beat SubStack https://theenergynewsbeat.substack.com/A shout-out to Steve Reese and the Reese Energy Consulting group for sponsoring the Podcast https://reeseenergyconsulting.com/.Data2 if you have any business systems, can you trust A? Well, they have the patent on validation. . https://data2.zoholandingpage.com/energyAnd we have WellDatabase rolling in as a new sponsor. https://welldatabase.com/

Artificial intelligence is transforming healthcare, but developing an AI medical device is only part of the challenge. Manufacturers must also navigate certification requirements and maintain safety and performance throughout the entire product lifecycle.In two podcast episodes featuring Sandy Wright and Osman El-Koubani, we explore the journey from certifying LLM-driven medical devices to managing them after CE marking.Certifying LLM-Driven Medical DevicesLarge Language Models such as ChatGPT, Gemini, and Claude introduce new regulatory challenges. Unlike traditional software, these systems raise questions around predictability, validation, traceability, supplier management, and model updates.Topics discussed include:What defines an LLM-driven medical deviceClinical evaluation strategiesDemonstrating clinical benefitUsing commercial AI modelsSupplier controls and external dependenciesSignificant changes and model updatesLife After CE MarkingObtaining CE certification is not the end of the journey.AI medical devices require continuous monitoring once they reach the market.Manufacturers must address:Performance drift in real-world settingsCollection and analysis of real-world dataAI retraining and change managementPredetermined Change Control Plans (PCCPs)Post-Market Surveillance (PMS)Continuous safety and performance evaluationAI Devices Require a Lifecycle ApproachAI systems are dynamic technologies. Success depends not only on achieving certification, but also on maintaining control over performance, updates, and clinical safety throughout the product lifecycle.As regulations continue to evolve, manufacturers must combine robust development practices with proactive post-market monitoring to ensure long-term compliance and patient safety.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkSandy LinkedIn: https://www.linkedin.com/in/wrightsandy/Osman Linkedin: https://www.linkedin.com/in/osman-kan/Scarlet Linkedin: https://www.linkedin.com/company/scarlet-comply/posts/?feedView=all&viewAsMember=trueSocial Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Robert Leshner is the Founder and CEO of Superstate, as well as the former CoFounder of Compound.Most people in DeFi are focused on the $2.5 trillion cryptonative market. Robert is focused on the $700 trillion that hasn't moved onchain yet. In this episode, he explains why tokenization is the long awaited evolution for crypto markets, how Superstate is building the bridge between institutional TradFi assets and DeFi, and why the benefits of tokenization will soon lead to a hockey stick moment in DeFi and RWAs.------

Animal identification and basic traceability has long been a reality for Canada's cattle and sheep sectors, and upcoming regulatory changes will bring the goat industry much closer to the same framework. While implementation timelines are still being determined, industry leaders say the changes are aimed at improving animal health response, disease management, and future market... Read More

How should Texas address rising property taxes, growing concerns about public safety, and the challenges facing the state's criminal justice system? On this episode of Texas Talks, host Brad Swail sits down with State Representative Mitch Little, who represents Texas House District 65 in southern Denton County, for a wide-ranging discussion on criminal justice policy, government regulation, property tax reform, and the priorities shaping the next legislative session. Little, an attorney and member of the Texas House Committee on Criminal Jurisprudence, shares insights from recent interim hearings and discusses how lawmakers are evaluating issues ranging from rural attorney shortages and elder fraud to prosecutorial accountability and public safety. The conversation covers: • Rural attorney shortages and the concept of “legal deserts” • Law school debt, workforce incentives, and market-based solutions • Elder fraud and cryptocurrency kiosk scams targeting seniors • Regulatory challenges surrounding cryptocurrency transactions • Public safety and criminal justice reform priorities • Rogue district attorneys and prosecutorial accountability • Governor Abbott's proposal for a statewide prosecutor • Judicial discretion, bail policy, and repeat offenders • Property tax reform and school finance • Government spending and affordability concerns • Priorities for the 90th Texas Legislature Little also explains why he believes many public policy debates should focus on underlying market realities rather than government subsidies, particularly when addressing workforce shortages in rural communities. The discussion explores broader concerns about law enforcement, prosecutorial discretion, judicial accountability, and the balance between local control and state oversight in Texas' criminal justice system. Looking ahead, Little identifies property tax relief as one of the most significant issues facing Texas families and outlines his perspective on how lawmakers can reduce the burden on homeowners while maintaining essential public services. 00:00 — Intro + Meet Rep. Mitch Little 01:50 — Representing Texas House District 65 03:00 — What interim hearings accomplish 06:00 — Rural attorney shortages and legal deserts 08:39 — Law school debt and workforce incentives 12:15 — Are rural legal shortages really a crisis? 14:01 — Comparing attorney and physician shortages 19:20 — Market solutions versus government subsidies 20:24 — Elder fraud and cryptocurrency scams 23:07 — Why crypto kiosks are being scrutinized 25:33 — Should Texas regulate or ban crypto kiosks? 29:13 — Rogue district attorneys and lawlessness concerns 32:42 — Governor Abbott's statewide prosecutor proposal 34:02 — Elections, appointments, and accountability 37:42 — Property taxes and legislative priorities 39:26 — How Texas could fund property tax relief 41:00 — Final thoughts and where to follow Mitch Little Watch Full-Length Interviews: https://www.youtube.com/@TexasTalks Follow us on social mediaX: @Texas_DispatchInstagram: thetexasdispatchLinkedIn: The Texas DispatchTikTok: texas_talks_podcast Find more at The Texas DispatchYour source for state news, policy, and investigative journalism.https://thetexasdispatch.com

“When your patient is your priority—getting them safe, highly pure, quality medicine—you're aligned with the health agency. That alignment and engagement really help.”Manda Pasarkar, Global Head of Regulatory Affairs CMC at Sanofi, has spent over 20 years mastering the intersection of chemistry and compliance—a rare combination that positions her at the forefront of pharmaceutical regulatory strategy.Pasarkar progressed from scientist roles at Teva through regulatory positions at Bayer, and now leads regulatory strategy for Sanofi's multi-billion dollar portfolio across biologics and small molecules, securing numerous drug marketing approvals in the US, EU, Japan, and China. She's also a Distinguished Toastmaster (DTM)—a designation fewer than 1% of Toastmasters International members achieve.In a recent PharmaSource podcast episode, Manda shared insights on navigating complex global regulatory landscapes, building productive agency relationships, leveraging ICH guidelines, working with CDMOs, and preparing for AI's impact on regulatory CMC.Read more.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Stay informed on current events, visit www.NaturalNews.com  - PJM Grid Crisis and Data Center Impact (0:10) - PJM's Reserve Shortfall and Price Controls (3:26) - Impact of Data Centers on PJM Grid (6:04) - Preparation for Power Outages (12:44) - Battery Technology and Future Investments (27:26) - IPOs and Market Bubbles (30:56) - Introduction of First Green Electric Skid Steers (54:09) - Advantages of Electric Skid Steers (1:05:56) - Challenges and Future of Electric Equipment (1:12:49) - Remote Control and Job Efficiency (1:22:42) - Skepticism and Operator Experience (1:27:35) - Product Models and Market Positioning (1:28:39) - Pricing and Maintenance (1:30:33) - Future of Electric Heavy Equipment (1:34:40) - Safety and Operator Training (1:44:13) - Customer Experience and Dealer Network (1:49:04) - Regulatory and Market Dynamics (1:52:02) - Future of Battery Technology (1:52:43) - Decentralized Living and Off-Grid Solutions (1:53:58) - Anniversary and Guest Announcements (2:25:52) - UNA Consultations and Market Demand (2:31:45) - Legal Recognition and Benefits of UNAs (2:35:07) - Risk Management and Liability (2:37:58) - Technology and Innovation (2:40:48) - Show Production and Guest Invitations (2:52:22) - Supporting Providers and Product Recommendations (2:52:38) - Closing Remarks and Future Plans (2:52:56) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here:

This is the afternoon All Local update for Tuesday June 9th, 2026.

What does the FDA's latest update on cosmetics regulation mean for beauty brands, manufacturers, and marketers? In this episode, we unpack how the FDA is expanding its oversight of the cosmetics industry through implementation of the Modernization of Cosmetics Regulation Act (MoCRA), the most significant overhaul of federal cosmetics regulation in more than 80 years. From mandatory facility registration, product listing, adverse event reporting, and safety substantiation requirements to forthcoming rules on good manufacturing practices, fragrance allergens, PFAS scrutiny, and talc testing, the agency is gaining unprecedented visibility into the cosmetics marketplace. As FDA signals that compliance, transparency, and product safety will remain key priorities, companies should prepare for heightened regulatory, litigation, and reputational risks in an increasingly scrutinized industry. Hosted by Simone Roach. Based on a blog post by Donnelly L. McDowell, Cristina Ferretti, and Katrina Hatahet.

Nick Jackson is the CEO and co-founder of Artist Partners, and collaborates with Andrew Mote, the Principal and Founder of Mote Advisors on analysing and advising superannuation funds on meeting their fiduciary responsibilities when it comes to their marketing investment. The explore the complexities of marketing within the Australian superannuation industry, focusing on regulatory scrutiny, measurement challenges, and strategic insights for marketers aiming to demonstrate member benefits and business outcomes. For a sector that manages more than $4.13 trillion in funds, making it one of the world's largest pension systems, and spending $482 million a year on marketing and sponsorship, this is an essential conversation to eavesdrop on. Listen on Apple: https://podcasts.apple.com/au/podcast/managing-marketing/id1018735190   Listen on Spotify: https://open.spotify.com/show/75mJ4Gt6MWzFWvmd3A64XW?si=a3b63c66ab6e4934   Listen on Stitcher: https://www.stitcher.com/show/managing-marketing   Listen on Podbean: https://managingmarketing.podbean.com/    For more episodes of TrinityP3's Managing Marketing podcast, visit https://www.trinityp3.com/managing-marketing-podcasts/   Recorded on RiversideFM and edited, mixed and managed by JML Audio with thanks to Jared Lattouf.

There's a quiet battle taking place, with no field hospitals for the sick and wounded, and no bloodshed.But the stakes are high, and the losses are unforgiving.It's the battle of algorithms.Employed by both payers and providers, the ultimate prize: money, in the form of reimbursement from submitted claims for medical care. Payers deny and recoup. Providers bill as margins shrink.During the next live edition of the ever-popular Talk Ten Tuesdays broadcast, senior healthcare analyst Frank Cohen, himself a veteran of algorithmic warfare, will escort you behind the front lines and into war rooms, so that you will have a better understanding of what is contributing to rising medical costs. Cohen's three-part article series on ICD10monitor.com begins this coming Tuesday.Other well-known subject-matter experts will also join the broadcast with more news to report, including the following:• POV: Penny Jefferson, cohost of Talk Ten Tuesday, will share her point of view (POV) during the broadcast.• CDI Report: Cheryl Ericson will provide an update on all things clinical documentation integrity (CDI).• The Coding Report: Christine Geiger will report on the latest coding news.

Regulatory volatility, scientific‑grade context requirements, and entrenched legacy processes are creating a level of operational complexity in pharma that makes even high‑value AI initiatives difficult to move from concept to production. In this episode, Art Shectman, CEO at Elephant Ventures, examines with host Marilie Fouché how leaders can cut through that complexity by isolating a single, clearly defined workflow slice and rebuilding it for near‑term, dependable deployment rather than long‑range architectural perfection. The discussion highlights how removing outdated process assumptions, selecting an atomic workflow with organizational alignment, and aiming for a contained operational win enable pharma teams to build momentum and scale AI responsibly in highly regulated environments. Learn how consultants are winning business with evidence-based AI ROI and building long-term capabilities instead of chasing short-term gains. Download our free PDF report, "3 Keys to Thriving in the Coming Era of Automation," at emerj.com/cok1

In this episode of Medsider Radio, we sat down with Kara Egan, founder and CEO of Teal Health.Teal Health is the company behind the first FDA-authorized at-home cervical cancer screening wand.Before founding Teal, Kara worked in healthcare and software investing at .406 Ventures and Emergence Capital, and held product and marketing roles at Zendesk and Stitch Labs.  In this interview, Kara discusses building support and follow-up into at-home screening, how Teal expanded its comparative clinical study to support broader market adoption, and how healthcare incentives, reimbursement, and institutional trust shape new care models.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Kara Egan, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:49) - Kara's background in health technology investing and software that shaped Teal's consumer-first approach (05:14) - How Teal turned the traditional Pap smear into the first FDA-authorized at-home screening product (07:30) - Turning at-home testing, telehealth, and clinician follow-up into a single care experience (13:48) - Raising Teal's first $1M with mockups and consumer-grade design (22:17) - Teal's comparative study that matched physician-collected screening with 96% sensitivity (23:40) - How asking women what they actually wanted changed Teal's view of the market opportunity (32:05) - “Take off the healthcare hat” — Kara's framework for fundraising, incentives, and commercialization (41:48) - What investors actually care about beyond the company's mission

At the heart of a recent lawsuit filed by a physician is whether the medical profession's understanding and practice of racial concordance is legally defensible.“Find-A-Black-Doctor” has served as a platform for Black, Indigenous, and Persons of Color (BIPOC) to locate providers who can offer them the best holistic treatment.However, some see this as discrimination against white-majority physicians, curtailing their access to potential patients.During my next live edition of Monitor Monday, Dr. Drew Updike, ] review the evidence behind concordance – as it pertains to women's health, BIPOC patients, and others – to provide you your team with an appreciation of its relevance in modern medicine.Broadcast segments will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Matthew Albright, chief legislative affairs analyst for Zelis, will report on current healthcare legislation.

California trucking companies continue to face mounting challenges from rising fuel prices, regulatory requirements, and increasing operating costs, according to industry leaders featured on a recent episode of the AgNet News Hour. During the program, Wildwood Trucking owner Mark Woods discussed the difficult business environment facing transportation companies that play a critical role in moving California's agricultural products across the state and nation. Woods said freight demand remains steady, but fuel expenses continue to put pressure on trucking operations and their customers. “We're still busy. We're working,” Woods said. “But this whole fuel thing has been really the biggest challenge.” Woods explained that while some customers pay fuel surcharges, many trucking companies are still absorbing significant increases in diesel costs. He noted that raising freight rates is not always a practical solution because growers, shippers, and receivers are facing their own economic pressures. The discussion also examined California's fuel tax structure and the broader impacts of state energy policies. Guest Ellington Smith, who writes regularly on energy and economic issues, argued that fuel taxes and fees have contributed significantly to higher gasoline and diesel prices in California compared to other states. Smith said California's fuel costs affect every sector of the economy, including agriculture, transportation, and manufacturing. He also expressed concerns about refinery closures and the state's reliance on imported fuel supplies. According to Smith, long-term energy infrastructure decisions could continue affecting costs for businesses and consumers alike. For agriculture, transportation remains a critical link in the supply chain. California growers depend on trucking companies to move fresh produce, nuts, dairy products, and other commodities from farms to processors, distributors, retailers, and export markets. Any increase in transportation costs ultimately affects the entire agricultural economy. Woods emphasized that trucking companies have already made significant investments in cleaner equipment and emissions technology while continuing to deliver products safely and efficiently. “Everything in your house, everything in your office has been delivered by an 18-wheel truck,” Woods noted during the interview. As California continues debating energy policy, fuel taxes, and economic development, transportation industry leaders say maintaining a competitive business environment will be essential for supporting agriculture and the broader economy. The conversation highlighted how closely tied fuel costs, freight transportation, and agricultural profitability have become throughout the state.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strategic withdrawal by Eli Lilly and Boehringer Ingelheim from planned investments in Germany. Both companies have decided to cut at least $1 billion each from their investments, a direct response to Germany's healthcare reforms targeting reduced branded drug prices. This decision highlights how governmental policy can significantly influence pharmaceutical investment strategies, prompting companies to be more cautious in markets with strict pricing controls. Another critical area of focus is clinical trials, where ADC Therapeutics has encountered a significant challenge. The company's antibody-drug conjugate, Zynlonta, which was granted accelerated FDA approval in 2021, recently reported three times as many deaths in its study arm compared to the control group. This raises important questions about the safety profile of antibody-drug conjugates, a class of drugs celebrated for their potential in targeted cancer therapy. The situation underscores the ongoing struggle to balance efficacy with safety in innovative cancer treatments. Regulatory oversight remains a pivotal aspect of the industry. The FDA recently issued a warning letter to Medline over recurring issues with toxic bacteria in finished products, emphasizing the critical need for compliance and safety within the medical device sector. Additionally, an untitled letter was sent to QOL Medical for potentially misleading promotional communications regarding Sucraid. Such actions demonstrate the FDA's vigilance in monitoring marketing practices that could mislead healthcare providers or patients. In drug approval news, AbbVie's Qulipta and Amgen's Imdelltra have secured approvals in Europe. These milestones are part of a broader strategy by pharmaceutical companies to expand geographically and enhance product portfolios through new indications. Meanwhile, Axsome Therapeutics successfully defended its narcolepsy medication Sunosi against generic competition until 2040 by settling patent litigation with a prospective generic manufacturer. This move reflects the intense patent battles common in the industry to extend product lifecycles and maintain market exclusivity. Turning to geopolitical influences, there is heightened scrutiny on China's biotech sector following calls from U.S. lawmakers for increased oversight. The potential application of the Comprehensive Outbound Investment National Security Act to Chinese biotech investments signals escalating tensions and could significantly impact international collaborations and investments. This reflects growing concerns over intellectual property protection and biotechnological advancements within international trade dynamics. In financial developments, Parabilis Medicines is preparing for an IPO with aims to raise $476 million to fund Phase 3 trials of its desmoid tumor drug candidate. This move illustrates continued investor interest in oncology innovations despite broader economic uncertainties. On the scientific front, Autobahn Therapeutics is making strides with its thyroid hormone receptor stimulator, showing efficacy in reducing depression symptoms in bipolar disorder during Phase 2 trials. This success paves the way for pivotal trials and highlights how hormone mimics can offer new therapeutic avenues for neuropsychiatric disorders. Meanwhile, Alnylam Pharmaceuticals has entered into a groundbreaking $2 billion agreement with Inceptive Nucleics to incorporate artificial intelligence into small interfering RNA design. By leveraging AI-driven methodologies, Alnylam aims to enhance precision and efficacy in siRNA therapies, potentially speeding up drug discovery processes. Operational challenges are also evident as companies navigate complex markets like Japan, underscoring the importance of integrating regulatory and strategic planning early on to mitigate risks and ensure market feasibility. These developments paint a vivid picture of a vibrant pharmaceutical and biotech landscape where scientific innovation is rapidly advancing alongside strategic partnerships and regulatory oversight. Breakthrough technologies such as AI-driven drug design hold promise for more targeted therapies while emphasizing personalized medicine approaches. However, these advancements come with challenges like safety concerns and regulatory compliance that demand constant vigilance and adaptability from industry stakeholders. The implications for patient care are significant as these scientific breakthroughs promise new treatment avenues for complex diseases while highlighting personalized medicine approaches. As these industries continue to evolve, staying informed about scientific innovations and regulatory landscapes will be crucial for stakeholders aiming to drive future growth and improve global health outcomes. Thank you for tuning into Pharma Daily. Stay informed and stay ahead with us as we continue to bring you the latest insights from around the pharmaceutical and biotech world.Support the show

Patrick McKenzie reads from his 2024 Bits About Money essay on ACATS, the Automated Customer Account Transfer Service that governs how Americans move investment accounts between brokerages, then updates it with regulatory developments (and industry infighting) from early 2026. The essay covers why a system underpinning trillions of dollars in assets was deliberately designed to skip verifying whether transfers are actually authorized, what the three-business-day shot clock means in practice, and how a bad actor armed with a stolen identity and a mobile app can drain someone's retirement account before they notice it's gone. (Good news, though: they'll almost certainly get it back. Bad news: quite stressful, and it often isn't obvious when staring at the zero that this is a recoverable condition.)–Full transcript available here: https://www.complexsystemspodcast.com/acats/ –Presenting Sponsors: Mercury & Granola If you have more interesting hobbies than managing your money, Mercury Personal is built for you. It allows you to automate movement between accounts—allocating paychecks and tax prep the moment they hit—with a sensible permissions model for partners or accountants. It works the way tech people expect banking to work. Go to mercury.com/personal to experience banking built by the same folks Patrick trusts for his business.If meetings consistently leave you with hazy action items and lost context, Granola handles the transcription so you can actually participate and gives you searchable notes afterward. Try it free at granola.ai/complexsystems with code COMPLEXSYSTEMS–Links:Guys what is wrong with ACATS: https://www.bitsaboutmoney.com/archive/how-acats-transfers-work/ –Timestamps:(00:00) Intro(01:49) A brief digression into self-regulatory organizations(03:04) FINRA regulates asset transfers between brokerages(04:54) How does one transfer securities account assets?(06:52) What does an ACATS request actually entail?(09:44) Brokerages frequently do not verify incoming ACATS requests(15:28) Recent developments in ACATS fraud(19:13) Should I be terrified, Patrick?(20:07) Sponsors: Mercury | Granola(23:17) Should I be terrified, Patrick? (cont'd)(24:46) Another fun wonky control(28:29) A final ACATS story(29:58) Regulatory updates: FINRA 26-02(32:34) Comment letters from the industry(43:20) Outro

(6) Michael Toth explains how Texas created specialized business courts and maintained a light regulatory touch to attract major corporations. The state is successfully challenging Delaware's dominance as the primary legal domicile for prominent American companies.

Join The Real Science of Sport Supporters club for ad-free listening and our exclusive weekly Applied Science show! A monthly donation is all takes!This week's Spotlight opens in Paris, where Roland Garros has delivered one of the most chaotic and compelling Grand Slams in recent memory, and ends on a Las Vegas track with a promise of $10 million unlikely to be fulfilled. Along the way, we explore retirements and comebacks, bike weight scandals, regulatory issues and a surprising way to boost your red blood cells.In today's Show:For the first time in the Open era, not a single former Grand Slam champion reached the men's round of 16. Ross and Gareth try to make sense of a tournament turned on its head by epically long five-set matches, multiple two-set-up defeats, and the emergence of potential new stars to challenge the duopoly atop men's tennisSinner is gone, Djokovic is gone, and the heat played a starring role. We revisit our applied show on heat adaptation to explain exactly why Sinner's implosion was both predictable physiologically, but surprising in its speed and persistenceSerena Williams has accepted a wildcard to play doubles at Queen's at 44. We explore the motivations for her return, and discuss why elite athletes retire in the first place? A thread on Discourse sparked by James gets us exploring the psychology and physiology of retirement, and why the grind we don't see is often the causeIn cycling, Lorena Wiebes was disqualified from the women's Giro after her bike allegedly weighed in 20 grams under the UCI's 6.8kg minimum. Was the punishment proportionate? Is the UCI's measurement process up to the required standard? Are SD Worx guilty of playing it too close to the limit? We discuss.A Belgian court has ruled against the UCI's attempt to impose gear ratio limits on the sport, finding the regulation neither necessary nor proportionate. We explore the implications well beyond cycling, and ponder how the UCI's failure to present a clear justification for the regulation was ultimately its undoingTilting your bed by six degrees could raise your EPO levels by 13% and increase hemoglobin mass by nearly 5%. Ross unpacks a genuinely fascinating new study, explaining why the mechanism is the same as altitude and heat training, whether the effect will be additive in athletes, and whether elite athletes are already quietly propping up their headboardsA carbohydrate question from supporter Tony ahead of his national canoe championships: does glycogen depletion in one muscle group affect availability elsewhere? Ross explains the elegant logic of local storage and use, the lactate shuttle, and why liver is the unsung hero of endurance fuellingAnd Finally, the Enhanced Games have announced a $10 million bonus for anyone who breaks Usain Bolt's 100m world record at their 2027 event. We discuss whether that will be enough to entice the truly fast man to race, doped or clean, and what it might mean for athlete's participation in the Olympics following an Enhanced Games Hosted on Acast. See acast.com/privacy for more information.

Hunting, Mental Prep, and Gear Tips with First Generation Bow HuntersIn this episode, Jason Dyer and Adam Buchanan share their experiences, gear insights, and mental strategies for a successful hunting season. Whether you're planning your first trip or a seasoned pro, get practical advice on equipment, mental prep, and how to maximize your time outdoors.WATCH huntwurx.com - new product coming!Main Topics:Strategies for mental resilience in hunting: handling close calls and unexpected encountersGear essentials: bow tuning, backup options, and innovative gear setupsPlanning and scouting: leveraging technology, mapping, and local knowledgeHunting success stories: elk, mule deer, antelope, and tips for applying for tagsSeasonal prep: fitness, equipment checks, and mental readinessCommunity and support: learning from others, sharing knowledge, and the importance of local contactsTimestamps:00:00 - Season kickoff: hunting mindset and preparation tips00:05 - Handling close encounters and mental resilience strategies00:30 - Elk hunting stories: near misses and learning from experience01:07 - The importance of safety and mental prep before the season01:47 - Gear talk: bows, rests, and backup plans in the field02:44 - Planning hunts: mapping, scouting, and weather considerations03:37 - Drawing tags: Utah deer, elk, and other over-the-counter opportunities04:54 - Overlapping seasons: mule deer, elk, and antelope strategies05:55 - Exciting upcoming events: Total Archery Challenge at high elevations06:23 - Equipment upgrades: bow modifications, setting pins, and gear organization07:01 - How to sight in complex gear like the Boonie sight07:52 - Mentorship and family hunts: passing knowledge to the next generation08:20 - Personal hunt stories and upcoming trips: Alaska caribou and more09:10 - The challenge of DIY hunting in remote Alaska10:11 - Cost considerations and planning for Alaska hunts10:56 - Most desired species: elk tops the list, sheep at the bottom11:45 - The allure and rarity of sheep hunting12:18 - Popularity rankings: mule deer, whitetail, and the appeal of antelope13:24 - Planning for next season: scouting, fitness, and flexible strategies14:06 - The thrill of extended archery seasons and hunting hotspots15:47 - The value of local knowledge and local contacts for big game success16:04 - Season preparation: gear, fitness, and logistical planning16:53 - The importance of calendar management, family time, and personal routines18:02 - The role of technology: apps like Skylight and Re Light hydration solutions24:47 - Navigating environmental factors: wind, terrain, and animal movement25:45 - Timing your hunts: understanding season windows and optimal conditions26:49 - Planning for multiple options: sustainable hunting plans and adaptability28:16 - Logistics management: scouting, movement, and timing on multi-day hunts29:36 - Regulatory considerations: avoiding issues with e-bikes and gear restrictions30:26 - Personal improvements: gear upgrades, fitness, and gear organization31:17 - Insuring gear integrity with innovative solutions like marine batteries37:25 - Staying informed and critical of new land use proposals39:23 - How to approach environmental impact statements and government projects40:24 - The value of scientific input versus political decisions in land management44:01 - Practical tips for storing and transporting gear like game sleds45:12 - Innovative gear for field dressing and animal transportation47:16 - Hunting plans for family, elders, and future generations48:38 - Reflections on mentorship, community, and evolving hunting goals50:16 - Recommendations for gear upgrades and hunting preparation52:13 - Personal goals for the upcoming season: family, exploration, and success55:00 - Cultivating the right mindset: purpose, patience, and community63:19 - Final thoughts: embracing the journey, gear, and community spirit in hunting

Loren Adler is a fellow and the associate director at the Center on Health Policy at the Brookings Institution. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L. Adler. Regulating Corporate Control in the U.S. Health Care System. N Engl J Med 2026;394:2073-2076.

Sponsor Medboard Medboard: https://www.medboard.com/EUROPEEurope Starts Regulating the Regulators - Implementing Regulation (EU) 2026/977: https://eur-lex.europa.eu/eli/reg_impl/2026/977/ojEUDAMED is mandatory - Panic is raising: https://health.ec.europa.eu/medical-devices-eudamed/overview_enGermany: https://www.bfarm.de/SharedDocs/Downloads/DE/Medizinprodukte/DMIDS-anleitung-anzeigepflichtige-mp-ivd.pdf?__blob=publicationFileBelgium: https://www.famhp.be/en/news/eudamed_clarifications_regarding_obligations_from_28_may_2026Portugal: https://www.infarmed.pt/web/infarmed/noticias/-/journal_content/56/15786/13092901AI Medical Devices - Timeline changed for AI ACT: https://www.consilium.europa.eu/en/press/press-releases/2026/05/07/artificial-intelligence-council-and-parliament-agree-to-simplify-and-streamline-rules/Germany guidance: https://www.bundesnetzagentur.de/DE/Fachthemen/Digitales/KI/5_Innovationen/_DL/Roadmap_Pilot.pdf?__blob=publicationFile&v=5Spain new HTA - Royal Decree 415/2026: https://www.boe.es/boe/dias/2026/05/29/pdfs/BOE-A-2026-11587.pdfDenmark on languages - Reminder that there are requirements to follow: https://laegemiddelstyrelsen.dk/en/devices/registration-and-marketing/language-requirement/UKMHRA regulatory advice meetings - Pay and ask what you want: https://www.gov.uk/guidance/medical-devices-ask-for-a-regulatory-advice-meeting-from-the-mhraEasy Medical Device solutionsEasyIFU - electronic Instruction for Use: https://easyifu.comSmarteye - electronic Quality Management System: https://eqms-smarteye.com/Rest of the WorldFDA reinforce Human Factors expectations - This is not nice to have: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissionsSaudi Arabia bundling criteria - More products in a single application: https://www.sfda.gov.sa/sites/default/files/2026-05/MDS-G28.pdfPodcastPodcast Nostalgia - Re-listen latest podcast episodes:Episode 390 - How can a proper intended use save your device with Kanrandeep Badwal: https://podcast.easymedicaldevice.com/390-2/Episode 391 - Feedback after 3 months of the new FDA QMSR is in place with Mathangi Srinivasan: https://podcast.easymedicaldevice.com/391-2/ Easy Medical DeviceConsulting activities (CE marking, Clinical Evaluation, QMS creation…) https://easymedicaldevice.com/services/mdr-ivdr-technical-documentation/BOSS Program: Back Office ServiceseQMS: https://easymedicaldevice.com/smarteye-eqms/EasyIFU: eIFU and Label creation: https://easymedicaldevice.com/easyifu/Authorized Representative in EU, UK and SwitzerlandMarket access all over the world: https://easymedicaldevice.com/services/market-access/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

What does a recovering clinical research market actually look like in 2026?In this episode, Joel White, Owner of Market Cap Consulting, and Ryan Gifford, Vice President, Global Laboratory Services, Business Development & Client Management at CTI, join us to unpack the state of the industry—from the rebound in biotech funding to the growing importance of execution, site relationships, and smarter trial design.We explore how increasing complexity is shaping partnerships, how labs and decentralized models are evolving, and what it will take to keep trials on track. Looking ahead, the conversation offers a practical perspective on what the next 12–18 months could bring. 01:00 Guest backgrounds: Joel White (Market Cap Consulting) and Ryan Gifford (CTI) 02:45 Market recovery and funding trends05:15 Trial success: early collaboration and site relationships08:15 Funding challenges and execution impacts 10:30 Reducing site burden through lab operations and logistics 14:15 Decentralized trials and patient experience16:25 Regulatory shifts, AI, and growing data complexity19:30 Future outlook: partnerships and global trial expansion 23:30 Key takeaways and rapid-fire insights

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we're speaking about how to best determine the efficacy of regulatory and quality team members. A variety of real-world examples are provided that demonstrate the need to “trust but verify” the actions of these team members. During this conversation, the following questions are addressed:Why the need to measure the safety and efficacy of the regulatory and quality team?What can happen if you put too much trust or reliance on your regulatory consultant?Can you give a specific example where there was too much trust?Can you give us another regulatory example, perhaps involving clinical trials?Can you provide a quality or manufacturing example, perhaps involving AI?What are today's takeaways?Listen to this discussion and see if you need a plan to verify your regulatory and quality team members' actions. If you'd like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com, and we'll see if your ideas/inquiries/suggestions align with a future episode.Send us Fan Mail For more medtech news and information, visit https://www.mpomag.com. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

EPISODE DESCRIPTION Something bigger than taxes is driving America's corporate headquarters out of blue states—and executives are finally saying it out loud. In this episode, we break down the accelerating migration of major companies like Exxon and Silicon Valley giants into red states, not for payroll or tax relief, but for something far more fundamental: the legal system itself. From claims of “hostile courts” and unpredictable verdict environments to high-profile cases shaping corporate risk calculations, this conversation explores whether America is splitting into competing legal realities—and what that means for business, politics, and the future of investment in the United States. OPENING HOOK Finally, somebody said the quiet part out loud. For years, we were told corporations were fleeing blue states because of taxes, unions, or cheaper labor. But now executives are saying something different entirely: It's the courts. Not the tax code. Not the workforce. The legal system itself. SEGMENT 1: THE GREAT CORPORATE RELOCATION Big corporations are moving headquarters out of states they've been in for decades. California, New York, New Jersey—places that once anchored American business power—are losing companies at a steady pace. And according to executives, it's not about simple economics anymore. It's about legal predictability. Companies are increasingly choosing jurisdictions where courts are seen as more stable, more consistent, and less politically driven. Florida and Texas keep coming up—not just for taxes, but for legal structure and federal court alignment. SEGMENT 2: THE EXXON SIGNAL The clearest admission yet comes from ExxonMobil. When the company moved its legal headquarters from New Jersey to Texas, leadership didn't center taxes as the deciding factor. Instead, they pointed to something more sensitive: “Regulatory environment” and “hostile courts.” Executives emphasized the importance of operating in a state where legislators, judges, and juries “understand the business” and where legal exposure feels more predictable. Even more significant, the company aligned itself with a federal court jurisdiction outside Houston—highlighting how granular legal geography has become in corporate strategy. SEGMENT 3: THE ZUCKERBERG EFFECT Tech is following a similar pattern. High-profile legal battles involving major platforms have raised concerns about jury-driven damages, regulatory pressure, and politically charged litigation environments. Meta's legal challenges in certain jurisdictions, particularly in California, have intensified debates about whether social media companies are being shaped through courts rather than legislatures. The result: increasing interest in relocating operational or legal structures to states seen as more protective. SEGMENT 4: JUDGE SHOPPING AND LEGAL STRATEGY Behind the scenes, corporate legal teams are adapting. One growing practice is “judge shopping”—strategically filing cases in jurisdictions believed to offer more predictable outcomes. This isn't new, but it's becoming more central to corporate survival strategy as legal variability increases between states and federal districts. The concern from executives is not just losing cases—but facing inconsistent legal interpretations depending on geography. SEGMENT 5: THE BROADER DIVIDE What emerges is a fractured map of the United States: Some states are seen as business-friendly legal environments Others are viewed as high-risk litigation zones Federal court districts are now part of corporate relocation strategy In this framework, companies aren't just choosing where to operate. They're choosing which legal universe they want to live in. CLOSING TAKE Whether this trend represents a correction, a warning sign, or a permanent restructuring of American legal geography, one thing is clear: Corporate America is no longer just following the money. It's following the courts. And that changes everything. ...

In the future, can autoimmune disease become curable? A groundbreaking study from Germany suggests there may be a pathway in some cases. Patients with severe, treatment-refractory lupus who received CD19 CAR-T cell therapy have remained in drug-free remission for up to five years without ongoing immunosuppression. In this episode, we discuss how these findings are shifting the conversation from disease control to the possibility of cure, and what they could mean for lupus, inflammatory myopathies, systemic sclerosis, vasculitis, rheumatoid arthritis, and autoimmune diseases more broadly. We also explore CAR-T therapy, immune resets, regulatory T cells, relapse risk, and the future of rheumatology with Dr. Georg Schett. 

Although one could conclude that artificial intelligence (AI) is a relatively new technology in healthcare, the reality is that AI has been silently working in the shadows for a while now.During the next live edition of the popular Talk Ten Tuesdays broadcast, you'll hear how AI is guiding the technology of the automated query technology at HITEKS, under the supervision of Gerasimos Petratos, founder and CEO.And what about the thousands and thousands of healthcare coders? Although AI is changing how healthcare claims are managed, as the technology takes on more straightforward coding tasks, coding professionals are shifting into higher-level validation, analysis, and oversight, according to Raemarie Jimenez, the president of membership for AAPC.Join us as we explore how AI is reshaping coding workflows and what coders should be preparing for now.Other well-known subject-matter experts will also join the broadcast with more news to report, including the following: POV: The legendary Rose Dunn, past president of the American Health Information Management Association (AHIMA), will serve as the guest cohost, sharing her point of view during the broadcast.CDI Report: Cheryl Ericson will provide an update on all things clinical documentation integrity (CDI).The Coding Report: Christine Geiger will report on the latest coding news.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

On today's Legally Speaking Podcast, I'm joined by three fantastic guests from the world of disputes. First, Loukas Mistelis, International Arbitration Partner at Clyde & Co, Professor of Transnational Commercial Law and Arbitration at Queen Mary University of London and Co-Chair of London International Disputes Week. Next, returning guest Henrietta (Hetti) Jackson-Stops, mediator, Partner of IPOS Mediation, founder of Simply Resolved, former Allen & Overy litigator, former Government lawyer, and currently leading the LegalTech Showcase at LIDW. And also returning to the show, Emilie Jones, Legal Director and Barrister at Pinsent Masons, Co-Chair of London International Disputes Week, specialising in commercial litigation and leading Pinsent Masons' Litigation and Regulatory practice development function.This episode is all about the modern litigator and arbitrator, and how legal tech and AI are changing dispute resolution in practice, not just in principle. Because the real question is no longer whether change is coming. It is what has actually changed, what is genuinely adding value, and what still depends on human judgment. So today, we are getting into the realities of modern disputes practice, the opportunities, the risks and what great litigators and arbitrators need to look like in 2026.So why should you be listening in? You can hear Rob, Loukas, Hetti and Emilie discussing:- Artificial Intelligence Enhancing Efficiency In Litigation, Arbitration and Mediation- Online Dispute Resolution Expanding Cross-Border Collaboration and Accessibility- Document Review Technology Transforming Complex Case Management- Human Judgment Remaining Essential Despite Rapid Legal Tech Adoption- Legal Professionals Focusing On Practical Value Beyond AI HypeConnect with Emilie Jones here - https://www.linkedin.com/in/emilie-j-a32415162Connect with Loukas Mistelis here - https://uk.linkedin.com/in/prof-loukas-mistelis-fciarb-0a736b1bConnect with Henrietta Jackson-Stops here - https://uk.linkedin.com/in/henrietta-hetti-jackson-stops-2331482

In this episode of Medsider Radio, we sat down with Karthik Ganesh, CEO of OnMed.OnMed is the healthcare technology company behind OnMed CareStation, a “Clinic-in-a-Box” designed to expand access to primary and urgent care. Before OnMed, Karthik served as CEO of EmpiRx Health, leading the company through rapid growth and a successful private equity transaction in 2021. Throughout his career, he's held leadership roles at QualCare, CareAllies, and Aetna, and advised healthcare organizations through Deloitte and EY.In this interview, Karthik discusses why hybrid care models still require a human touch, how enterprise healthcare buyers evaluate value propositions differently, why brand and culture should shape execution early, and how operating under constraints can sharpen innovation.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Karthik Ganesh, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:04) - Karthik's obsession with healthcare access, and the “broken doorway” problem behind OnMed (05:51) - How OnMed combines telemedicine and brick-and-mortar care into a “Clinic in a Box” (09:04) - The OnMed metrics that surprised Karthik most, including a 37% patient return rate, and the reasons behind the company's success (09:22) - What OnMed designed differently after realizing that patients approach healthcare with their guard up (15:27) - The pitfalls of B2C healthcare and how OnMed was built as a B2B company by intention (22:01) - How Karthik reshaped OnMed around clarity, structure, and high performers (30:23) - What “brand” actually means to Karthik (39:37) - How OnMed tailored its value proposition for payers, providers, employers, and universities (45:45) - Karthik's fundraising philosophy: constraints keep companies inventive

It's that bright new shiny object few seem to manage to resist: artificial intelligence (AI).Here at RACmonitor and Monitor Mondays, we have been reporting on how this disruptive technology has been altering the compliance landscape.And we will continue that reporting. AI is rapidly reshaping healthcare auditing and compliance, and as organizations move toward greater claim visibility and AI-driven review processes, what does that mean for audit exposure, risk, and oversight? Join us during the next live edition of the venerable Monitor Mondays broadcast for an incredible journey, as Pam Warren explores how AI is changing the compliance landscape, and what organizations should be thinking about now. Warren, from AAPC, is the manager of regulatory billing audits for MaineHealth in Maine, the largest healthcare system in Northern New England.Broadcast segments will also include these instantly recognizable features:·      Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. ·      The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. ·      Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.·      Legislative Update: Cate Brantley, senior legislative affairs liaison for Zelis, will report on current healthcare legislation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development. Pfizer's monumental $10 billion collaboration with Innovent Biologics stands out as a testament to the shifting dynamics of the oncology sector. This partnership aims to develop 12 antibody-drug conjugate (ADC) and multispecific antibody programs, spotlighting these therapies' growing significance in oncology. The precision of antibodies in delivering cytotoxic agents directly to cancer cells offers a new frontier in minimizing collateral damage to healthy tissues—a crucial advancement in cancer treatment. The deal not only highlights Pfizer's commitment to expanding its oncology pipeline but also underscores the strategic importance of leveraging China's accelerated drug development ecosystem. In regulatory news, AstraZeneca's Imfinzi has garnered FDA approval for BCG-naive high-risk non-muscle-invasive bladder cancer. This milestone for PD-L1 inhibitors reflects the evolving landscape of immunotherapy. By harnessing monoclonal antibodies in combination therapies, the potential for enhanced anticancer efficacy is significant. With few therapeutic alternatives available, this approval presents a lifeline for many bladder cancer patients. Clinical trial outcomes also continue to capture attention. Eli Lilly's Nectin-4 targeting ADC showed promising results in advanced urothelial cancer, positioning itself as a potential competitor to Padcev. This innovation in ADC technology demonstrates the industry's relentless pursuit of targeted therapies that can revolutionize treatment paradigms. Bristol Myers Squibb's mezigdomide offers another example by showing a 52% reduction in progression risk for relapsed or refractory multiple myeloma patients, emphasizing the focus on addressing specific molecular pathways. In the realm of bispecific antibodies, Phanes Therapeutics' CLDN18.2/CD47 targeting therapy reported encouraging Phase 2 results in metastatic pancreatic ductal adenocarcinoma. These antibodies' ability to simultaneously engage multiple targets enhances their therapeutic efficacy against stubborn cancers, broadening the horizon for treatment possibilities. Meanwhile, Replimune's resubmission of its RP1 melanoma Biologics License Application (BLA) highlights the intricate dance between drug development and regulatory processes amid organizational shifts at the FDA. Such efforts reflect the continual adaptation required within the industry to navigate complex regulatory landscapes. On the funding front, Psilera's successful $8.8 million seed round indicates growing interest in psychedelic therapies for neurological conditions. Similarly, Reprogram Biosciences raised $6 million for its AI-driven cell reprogramming oncology platform, illustrating how artificial intelligence is becoming integral to advancing drug discovery and development. However, not all updates were positive. Agios Pharmaceuticals faced setbacks as their pyruvate kinase activator failed a Phase 2b trial for lower-risk myelodysplastic syndromes, serving as a sobering reminder of the inherent risks involved in drug development. Dizal Pharma emerges as a beacon of hope in lung cancer treatment following Takeda's EGFR exon 20 drug setback. By challenging existing treatments with promising small molecule data, Dizal exemplifies precision medicine's role in redefining oncology protocols—offering personalized patient options that could set new standards in treatment efficacy. The issue of drug pricing remains contentious, particularly highlighted by an AARP analysis showing an 81% increase post-launch prices stateside compared to a 13% decrease abroad. This disparity raises critical questions about achieving equitable access across markets amid Medicare negotiations and global pricing strategies like "most favored nation" policies. Regulatory updates continue with Johnson & Johnson's Tremfya label expansion stateside and AbbVie's EU extension for Venclyxto—moves that reflect efforts to maximize therapeutic reach and commercial viability across diverse geographies. Finally, Gilead Sciences' decision to discontinue its lead rheumatoid arthritis drug from MiroBio underscores ongoing challenges within emerging fields like BTLA agonists—a reminder of both innovation's promise and its perilous nature when faced with unproven therapeutic avenues. As these varied developments unfold, they collectively signal an era characterized by rapid scientific innovation and strategic collaborations across geographies alongside evolving regulatory landscapes—all driving towards enhanced patient care through more effective treatments globally. This concludes today's insights from Pharma Daily—a world where dynamic change continues reshaping healthcare delivery standards towards unprecedented possibilities for patient outcomes worldwide. Thank you for joining us; stay tuned for more updates on tomorrow's horizon-shaping advancements.Support the show

Brad Carson was the Army's General Counsel, served two terms in Congress and was Acting Under Secretary of Defense for Personnel and Readiness. He now heads Americans for Responsible Innovation, the AI-policy advocacy group he co-founded. Keith Duggar spends roughly eighty minutes pushing back.SPONSOR:---Cyber Fund built the Monastery to help founders ship products that were impossible a year ago. Applications for Batch 1 are now open.Apply now: https://cyber.fund---Carson's whole case rests on one line: the genie is not out of the bottle. We have pulled dangerous tech back before. Asilomar halted recombinant DNA in 1975, and the West still controls the chips AI runs on. Calling it unstoppable, he says, is the most dangerous idea in the room.Then Keith drags him somewhere darker. A Palantir heat map scores you 0.73 on whether you are a combatant, and a strike follows. The model is wrong some accepted share of the time, and when it is, nobody answers for it. You cannot court-martial a model, and not even the interpretability researchers can say why it picked you.—Note: after recording, we learned that Americans for Responsible Innovation is backed by EA-aligned philanthropy (not sponsored)---TIMESTAMPS:00:00:00 From the Pentagon to AI governance00:04:52 Regulatory capture vs Silicon Valley networks00:07:56 Transparency and the Claude tier changes00:09:40 Tort liability when AI tools cause harm00:13:40 AI is a product, not a person00:16:01 Children, suicide, and the suicide business00:19:59 Opaque neural nets and the law of war00:25:54 Probabilistic targeting and the death of accountability00:28:47 The arms race fallacy: Asilomar and restraint00:34:02 Talking to China: track 2 talks and chip leverage00:39:45 Air power never wins: capital for labour00:43:29 Anthropic vs the Department of War00:51:29 Concentration, open source, and brain drain01:00:18 DeepSeek, Chinese culture, and AI as diplomacy01:12:25 Upskilling Congress and why public trust matters---REFERENCES:organization:[00:02:45] ICRC position on autonomous weaponshttps://www.icrc.org/en/law-and-policy/autonomous-weapons[00:05:22] Americans for Responsible Innovation (ARI)https://ari.us[00:07:20] Andreessen Horowitz (a16z)https://a16z.com/[01:16:05] Office of Technology Assessmenthttps://en.wikipedia.org/wiki/Office_of_Technology_Assessmentother:[00:03:35] Beneficial AGI 2019 Conference (Future of Life Institute, Puerto Rico)https://futureoflife.org/event/beneficial-agi-2019/[00:18:30] Section 230 of the Communications Decency Acthttps://en.wikipedia.org/wiki/Section_230[00:19:59] Lethal Autonomous Weapons (LAWS)https://en.wikipedia.org/wiki/Lethal_autonomous_weapon[00:31:35] Strategic Arms Limitation Talks (SALT)https://en.wikipedia.org/wiki/Strategic_Arms_Limitation_Talks[00:32:28] Asilomar Conference on Recombinant DNA (1975)https://en.wikipedia.org/wiki/Asilomar_Conference_on_Recombinant_DNA[00:39:45] The New Iron Triangle (ARI policy byte)https://ari.us/policy-bytes/the-new-iron-triangle/[00:48:05] Defense Production Acthttps://en.wikipedia.org/wiki/Defense_Production_Actperson:[00:03:35] Anthony Aguirrehttps://en.wikipedia.org/wiki/Anthony_Aguirre[00:06:48] Dean Ball — Hyperdimensionalhttps://www.hyperdimensional.co/[00:23:13] Neel Nanda — mechanistic interpretabilityhttps://www.neelnanda.io/[00:36:02] Jack Clark (Anthropic) on Conversations with Tylerhttps://conversationswithtyler.com/episodes/jack-clark/[00:39:15] Robert Trager — Centre for the Governance of AIhttps://www.governance.ai/team/robert-trager[00:41:55] Giulio Douhethttps://en.wikipedia.org/wiki/Giulio_Douhet[01:15:05] Don Beyer (US Congress)https://en.wikipedia.org/wiki/Don_Beyertool:[00:22:19] Phalanx CIWShttps://en.wikipedia.org/wiki/Phalanx_CIWS---ReScript:https://app.rescript.info/public/share/9405ff35c0215b7cdae6402d41284171https://app.rescript.info/api/public/sessions/0a6c081b8e5fe413/pdf

Part 2 of our new format with three frontier founders: Guillermo Rauch (Vercel), Blake Scholl (Boom Supersonic), and Max Hodak (Science).  00:00 Previously… 00:34 The Regulatory Red Queen Race 05:13 Why There's No Innovation in Health Care 09:30 We Need a True 50-State Experiment 13:12 China's FDA Is Beating Ours 16:18 Healthcare Is a Communist Society Inside Capitalism 18:38 Sid's Story: N-of-1 Medicine Transcript: nav.al/regulatory

What if one of the most toxic products in your home isn't your cleaning spray, your cookware, or your water bottle… but the lip gloss sitting in your purse right now? In this eye-opening and deeply alarming conversation, Darin Olien sits down with clean beauty innovator, attorney, and consumer advocate Laura D'Alamo to expose what may be one of the biggest blind spots in modern health and beauty. After surviving triple-negative breast cancer and a near-fatal battle with COVID, Laura embarked on a two-year investigation into the cosmetic industry that uncovered a startling regulatory gap surrounding lip products, microplastics, toxic ingredients, and consumer safety. Together, they explore how lip products are regulated as external-use cosmetics despite being chronically ingested, why 80–90% of lip products may contain microplastics, how outdated regulations fail to reflect modern usage patterns, and why ingredients banned in food can still legally appear in products applied directly to the lips. They also discuss the launch of the Lip Service Alliance, the future of food-grade lip care, and how consumers can drive industry-wide change through awareness and purchasing decisions.     What You'll Learn Why lip products may represent a major overlooked toxic exposure pathway How cosmetics regulations differ from food and pharmaceutical regulations Why lip products are treated as external-use products despite being ingested The hidden role of microplastics in lip glosses, lipsticks, and lip balms Why flavored lip products may increase chronic ingestion How lip tissue differs biologically from normal skin The shocking absorption rates associated with oral mucosal tissue Why titanium dioxide is banned in European food but still used in lip products How outdated usage assumptions fail to reflect modern beauty habits Why the fastest-growing lip product market is girls ages 9–17 The mission behind the Lip Service Alliance How consumers can influence change through their purchasing decisions     Chapters 00:00:04 – Welcome to SuperLife 00:00:33 – Sponsor: Manna Vitality and frequency-enhanced wellness 00:01:59 – Introducing Laura D'Alamo and today's hidden toxic threat 00:02:35 – Triple-negative breast cancer and Laura's life-changing diagnosis 00:02:42 – Surviving COVID in the ICU and a profound existential awakening 00:03:00 – The cosmetic regulatory blind spot that changed everything 00:03:49 – Lip products containing thousands of microplastics per application 00:04:14 – Titanium dioxide, food bans, and regulatory contradictions 00:04:50 – The creation of the Lip Service Alliance 00:05:20 – Building the first food-grade lip care alternative 00:05:38 – Laura's legal background and journey through clean beauty 00:07:10 – Creating one of the first modern clean deodorant brands 00:08:23 – Innovation, consumer behavior, and predicting market shifts 00:09:29 – Consulting global beauty brands and seeing industry patterns 00:10:06 – Cancer diagnosis, purpose, and personal transformation 00:11:34 – Chemotherapy, ICU survival, and reevaluating life's mission 00:13:15 – The moment everything clicked into focus 00:13:59 – Returning to law and studying cosmetic regulations 00:14:25 – Why cosmetic regulations rarely keep pace with innovation 00:15:00 – Outdated assumptions still shaping modern beauty products 00:16:02 – Regulations built around usage patterns from decades ago 00:16:49 – Why this is a global issue—not just a U.S. problem 00:17:13 – Discovering the biggest blind spot in beauty history 00:18:15 – The late-night realization that launched two years of research 00:19:16 – Lip products classified as external-use cosmetics 00:21:02 – Why lip products are inevitably ingested 00:21:37 – Food-flavored lip products and TikTok taste-test culture 00:22:58 – Regulatory frameworks largely ignoring ingestion 00:23:53 – The EU's outdated lipstick usage assumptions 00:24:49 – The lead-in-lipstick controversy revisited 00:25:16 – Modern beauty consumers layering multiple lip products 00:26:16 – Heavy metals, PFAS, plastics, and cumulative exposure 00:27:12 – The $14 billion lip industry explained 00:27:34 – Why ages 9–17 are the fastest-growing demographic 00:29:00 – The shocking microplastic content of many lip products 00:29:44 – Why "clean beauty" often creates consumer confusion 00:30:15 – Hidden plastics even inside clean-positioned products 00:32:24 – Titanium dioxide and the food-versus-cosmetics paradox 00:33:20 – Genotoxicity concerns and cancer-related research 00:34:08 – Why regulators continue allowing it in lip products 00:35:04 – "You may love your lip products—but do they love you back?" 00:35:26 – The biological difference between lip tissue and skin 00:36:34 – Lip tissue as a highly absorbent biological portal 00:37:52 – Why standard skin testing may be misleading 00:38:17 – Testosterone, nicotine, and oral absorption comparisons 00:39:08 – Chronic exposure through ingestion and absorption 00:40:12 – Common sense versus regulatory assumptions 00:41:13 – Why parents react differently when children are involved 00:42:25 – The disconnect between protecting children and protecting ourselves 00:43:19 – Plastic detox research and fertility improvements 00:44:12 – Chronic inflammation and long-term health implications 00:45:07 – Quick wins consumers can implement immediately 00:45:47 – Why Laura spent two years building solutions before speaking publicly 00:46:30 – Launching the Lip Service Alliance 00:47:14 – Consumer awareness as the first step toward change 00:48:10 – Voting with your wallet and shifting industry behavior 00:48:52 – New scientific publications currently in peer review 00:49:50 – Creating new testing models for lip-specific safety 00:50:10 – Lip tissue absorbing up to hundreds of times faster than skin 00:51:00 – Why flavoring products encourages ingestion 00:52:14 – Petroleum-derived ingredients and bioaccumulation concerns 00:54:03 – Creating YAM: a 100% food-grade lip care company 00:55:29 – Building completely plastic-free packaging solutions 00:56:47 – Bioavailable ingredients and supporting natural lip biology 00:58:02 – The "dual pathway" problem: ingestion and absorption 00:59:00 – Hidden solvents and natural flavor loopholes 01:00:07 – Developing future food-grade lip products 01:01:04 – Why food-safe colorants are often illegal in cosmetics 01:02:28 – Regulatory barriers blocking safer innovation 01:03:37 – Simple policy changes that could transform the industry 01:04:23 – Darin reflects on Laura's relentless mission 01:05:32 – Why food-grade ingredients may work better biologically 01:06:21 – Regulatory modernization still missing lip-specific reforms 01:07:07 – The frustration of slow-moving bureaucracy 01:07:36 – Europe's timeline for microplastic warnings and bans 01:08:44 – Why consumers cannot afford to wait until 2035 01:09:29 – The aerosol-can analogy and how industries can change 01:09:49 – The role of consumer awareness and public pressure 01:10:38 – Why many brands don't even realize what's inside their formulas 01:11:18 – Inflammation, chronic exposure, and final warnings 01:11:57 – Closing thoughts and the future of lip safety advocacy     Thank You to Our Sponsors Shakeology: Get 15% off with code DARINO1BODI at Shakeology.com. Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order.     Join the SuperLife Community Get Darin's deeper wellness breakdowns — beyond social media restrictions: Weekly voice notes Ingredient deep dives Wellness challenges Energy + consciousness tools Community accountability Extended episodes Join for $7.49/month → https://patreon.com/darinolien     Find More from Laura DiGirolamo Website: https://yombeauty.com/  Instagram: @meetlauradigi Join: Lip Service Alliance     Find More from Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness      Key Takeaway "The biggest health threats are often the ones hiding in plain sight. Lip products are uniquely positioned at the intersection of ingestion, absorption, and chronic exposure, yet most regulatory systems still treat them as if they simply sit on the surface of the skin. Whether or not every concern raised in this conversation proves true over time, one thing is undeniable: consumers deserve better science, better transparency, and better products. And when enough people demand change, industries always find a way to evolve."

Send us Fan MailIn this fast-paced episode of Neo News, Eli and Ben tackle the rapidly shifting landscape of vaccine regulation and economics in the US. They discuss recent political maneuvers surrounding the Vaccine Injury Compensation Program (VICP) and how expanding liability could quietly push manufacturers out of the market entirely. The hosts also examine the FDA's recent hesitation to review Moderna's new mRNA flu vaccine, highlighting how these administrative roadblocks threaten the financial viability of developing novel vaccines—including critical immunizations for pediatric and neonatal populations. Tune in for a sharp analysis of how top-down policy changes might reshape everyday clinical practice!----1) https://thehill.com/policy/healthcare/5689850-kennedy-dismisses-vaccine-advisors/2) https://www.washingtonpost.com/opinions/2026/01/15/rfk-jr-vaccines-autism-vicp/3) https://www.nytimes.com/2026/02/18/health/fda-moderna-flu-vaccine-mrna.html4) https://www.nytimes.com/2026/02/16/health/rfk-vaccine-manufacturers.htmlSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Joshua Silver has spent two decades in embedded payments. Before co-founding Rainforest, he built Patient Co, a healthcare payments business scaled to billions in processing volume and tens of millions of patients, then spent several years consulting with software founders on building their payments programs. Rainforest is payments as a service, purpose-built for vertical SaaS — and in this conversation Joshua makes a compelling case that embedded payments is not just a revenue opportunity but a competitive moat.What We CoveredWhy vertical SaaS companies are still leaving money on the table with embedded paymentsThe gap in the market Rainforest was built to fillHow payfac as a service works and who it is designed forWhy the number of registered payfacs is shrinking, not growingThe $5 billion volume threshold for when becoming a full payfac makes economic senseHow Rainforest differentiates from Stripe and Adyen for vertical SaaS platformsVertical-specific risk models versus general-purpose toolsRainforest's real-time ledger and what it unlocks for complex payment structuresAdding PayPal and Venmo for untapped vertical SaaS marketsExpanding into Canada and building the playbook for international growthHow AI is being used across the business and the rising threat of AI-driven fraudWhat success looks like for Rainforest in the next five yearsKey TakeawaysEmbedded payments builds a moat. Joshua's closing point is the sharpest: once merchants are running their money through your software platform, competitors face a much harder job dislodging you. Payments isn't just a revenue line — it's a retention strategy.Vertical-specific risk models matter enormously. Stripe and Adyen have to serve everyone, so their risk tooling is built for the lowest common denominator. Rainforest has built models tuned to individual verticals — lawn care looks different from HVAC, which looks different from nonprofit donations — and it takes the fraud liability rather than passing it to the platform.The $5 billion payfac threshold is the new reality. A decade ago the rule of thumb was around $1 billion in card volume. Regulatory and compliance burdens have risen so sharply that Joshua now puts the threshold at $5 billion with line of sight to $10 billion before it makes economic sense to go full payfac.A real-time ledger is a competitive differentiator. Most legacy processors are batch-based, settled overnight on mainframes. Rainforest's ledger is real-time, enabling split payments, franchise fee hierarchies, and complex billing structures that batch systems simply cannot support.About Joshua SilverJoshua Silver is co-founder and CEO of Rainforest, a payments-as-a-service company purpose-built for vertical SaaS platforms. Before Rainforest, he co-founded Patient Co, scaling it to billions in healthcare payments volume before a sale, and subsequently consulted with software founders on building their payments businesses. He has been working in embedded payments for twenty years.Connect with Fintech One-on-One:Tweet me @PeterRentonConnect with me on LinkedInFind previous Fintech One-on-One episodes